EGFR and metastatic colorectal cancer: Optimal sequence of molecular targeted agents including antibodies against epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, and vascular endothelial growth factor, such as bevacizumab, is clinically important for the treatment of metastatic colorectal cancer (mCRC).1, 2